,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'enhertu', 'daiichisankyous', 'fierce', 'astrazeneca']
with phenomenally spectacular data at #asco22, and 's enhertu could transform how breast cancer is treated by opening a new category: her2-low. 
Tweets from the Fierce Life Sciences editorial team